Mondego Bio
Pre-clinicalHeadquartered in Portugal’s main biotech park, Biocant, Mondego Bio is developing best-in-class Protein tyrosine phosphatase non-receptor type 2 (PTPN2) inhibitors, providing a potential immuno-oncological therapy with an improved safety and tolerability profile.
Founded
2019
Focus
OncologyImmunologyAntibodies
About
Headquartered in Portugal’s main biotech park, Biocant, Mondego Bio is developing best-in-class Protein tyrosine phosphatase non-receptor type 2 (PTPN2) inhibitors, providing a potential immuno-oncological therapy with an improved safety and tolerability profile.
Funding History
2Total raised: $17.5M
Series A$15MSofinnova PartnersNov 15, 2023
Seed$2.5MPortugal VenturesJun 15, 2022
Company Info
TypePrivate
Founded2019
LocationCoimbra, Portugal
StagePre-clinical
Contact
SIMILAR COMPANIES
Bial
Pre-clinical · Porto
Biopremier
Pre-clinical · Lisbon
Laboratorios Atral
Pre-clinical · Cantanhede
FairJourney Biologics
Pre-clinical · Porto
Sea4Us
Pre-clinical · Lisbon
Is this your company?
Claim your profile to update information, add pipeline data, and connect with investors.
Claim profile